



Friday, Sept. 26th, 2025 8:45 am - 5:10 pm Pacific Time

Gene Therapy Challenges and Best Practices: From Discovery to IND and Beyond (jointly by PBSS and RAPS-SF)

Organizers: Toufan Parman, PhD, DABT, Alector; Yoshiko Stowell, PhD, Kenai Therapeutics

San Francisco Bay Area: Crowne Plaza Foster City; available as webcast to other PBSS chapters



Michael Templin, PhD, DABT
 Director, Scientific Advisory Services,
Charles River Laboratories

Forging a New Path: The Journey From
 Discovery to Clinical Trials With a Gene therapy



Aaron DeLoughery, PhD
 Principal Scientist, Protein discovery,
Mammoth Biosciences

Discovery of NanoCas, an Ultracompact CRISPR
 Nuclease Capable of Single-AAV Editing of
 Skeletal Muscle in Non-human Primates



Kathleen Meyer, PhD, DABT
 VP, Development Sciences,
Sangamo Therapeutics

Laying the Groundwork: Nonclinical Strategies in
 Gene Therapy Development



Toufan Parman, PhD, DABT
 Head of Nonclinical Sciences,
Alector

Genotoxicity and Carcinogenicity of Cell Therapies
 Utilizing Adeno-Associated Viral Vectors



Yanmei Lu, PhD
 VP, Biomarker and BioAnalytical
 Sciences, **Sangamo Therapeutics**

Navigating Companion Diagnostic Development for
 AAV Gene Therapy in the US: A Drug Sponsor's View



Cori Gorman, PhD, MBA
 Previously: Senior Director,
 Biopharmaceutical CMC and
 Regulatory Affairs, **Cencora-
 Pharmalex**

What Role Can RNA Therapeutics Play in Gene
 Therapies?



John Shoffner, MD, FACMG
 Retired; previously at Novartis, Sangamo
 Therapeutics, and Astellas Pharma

rAAV Gene Therapies for Rare Neurological
 Diseases: Clinical Development Considerations



Sandeep Yadav, PhD
 VP, Technical Development,
Sangamo Therapeutics

Challenges and Opportunities with AAV Derived
 Genomic Medicines - a CMC Perspective



Michael Molony, MA
 Executive Director, Analytical
 Development & Quality Control,
Insmed Inc.

Analytical Development and Quality Control
 Overview for AAV Gene Therapies from R&D to BLA



Tiffany Lucas, PhD
 Principal Consultant - CMC Cell &
 Gene Therapy Regulatory Affairs,
ELIQUENT Life Sciences

Past Guidance, Future Uncertainty: Interpreting
 FDA Guidance Documents Amid Leadership Shifts
 in Gene Therapy



Registration: <https://www.pbss.org>

- Regular Attendees: \$295 (Registration closes one day before the event or when full)
- Academic or Out-of-Pocket: \$45 (Registration closes five days before the event)





Friday, Sept. 26th, 2025 8:45 am - 5:10 pm Pacific Time

Gene Therapy Challenges and Best Practices: From Discovery to IND and Beyond (jointly by PBSS and RAPS-SF)

Organizers: Toufan Parman, PhD, DABT, Alector; Yoshiko Stowell, PhD, Kenai Therapeutics

San Francisco Bay Area: Crowne Plaza Foster City; available as webcast to other PBSS chapters

Time (PT)	Topic	Presenter(s)
8:45 - 9:05 am	PBSS Overview	Shichang Miao , PhD, PBSS President; Yoshiko Stowell , PhD, RAC, PMP, Chapter Chair, RAPS-SF
9:05 - 9:30 am	Forging a New Path: The Journey From Discovery to Clinical Trials With a Gene therapy	Michael Templin , PhD, DABT, Director, Scientific Advisory Services, Charles River Laboratories
9:30 - 10:00 am	Discovery of NanoCas, an Ultracompact CRISPR Nuclease Capable of Single-AAV Editing of Skeletal Muscle in Non-human Primates	Aaron DeLoughery , PhD, Principal Scientist, Protein discovery, Mammoth Biosciences
10:00 - 10:55 am	Laying the Groundwork: Nonclinical Strategies in Gene Therapy Development	Kathleen Meyer , PhD, DABT, VP, Development Sciences, Sangamo Therapeutics
10:55 - 11:05 am	<i>Morning Sponsor</i>	<i>Labcorp Biopharma Solutions</i>
11:05 - 11:25 am	<i>Break</i>	-
11:25 - 11:55 am	Genotoxicity and Carcinogenicity of Cell Therapies Utilizing Adeno-Associated Viral Vectors	Toufan Parman , PhD, DABT, Head of Nonclinical Sciences, Alector
11:55 am - 12:55 pm	<i>Lunch</i>	<i>Sponsor (TBD)</i>
12:55 - 1:25 pm	Navigating Companion Diagnostic Development for AAV Gene Therapy in the US: A Drug Sponsor's View	Yanmei Lu , PhD, VP, Biomarker and BioAnalytical Sciences, Sangamo Therapeutics
1:25 - 1:50 pm	What Role Can RNA Therapeutics Play in Gene Therapies?	Cori Gorman, PhD , Previously: Senior Director, Biopharmaceutical CMC and Regulatory Affairs, Cencora-Pharmalex
1:50 - 2:20 pm	rAAV Gene Therapies for Rare Neurological Diseases: Clinical Development Considerations	John Shoffner , MD, FACMG, Retired; previously at Novartis, Sangamo Therapeutics, and Astellas Pharma
2:20 - 2:50 pm	Challenges and Opportunities with AAV Derived Genomic Medicines - a CMC Perspective	Sandeep Yadav , PhD, VP, Technical Development, Sangamo Therapeutics
2:50 - 3:40 pm	Analytical Development and Quality Control Overview for AAV Gene Therapies from R&D to BLA	Michael Molony , MA, Executive Director, Analytical Development & Quality Control, Insmad Inc.
3:40 - 3:50 pm	<i>Afternoon Major Sponsor</i>	<i>TBD</i>
3:50 - 4:10 pm	<i>Break</i>	-
4:10 - 4:40 pm	Past Guidance, Future Uncertainty: Interpreting FDA Guidance Documents Amid Leadership Shifts in Gene Therapy	Tiffany Lucas , PhD, Principal Consultant - CMC Cell & Gene Therapy Regulatory Affairs, ELIQUENT Life Sciences
4:40 - 5:10 pm	Panel Discussion	-
5:10 - 6:10 pm	Happy Hour	Sponsor (TBD)

Registration: <https://www.pbss.org>

- Regular Attendees: \$295 (Registration closes one day before the event or when full)
- Academic or Out-of-Pocket: \$45 (Registration closes five days before the event)





Friday, Sept. 26th, 2025 8:45 am - 5:10 pm Pacific Time

Gene Therapy Challenges and Best Practices: From Discovery to IND and Beyond (jointly by PBSS and RAPS-SF)

Organizers: Toufan Parman, PhD, DABT, Alector; Yoshiko Stowell, PhD, Kenai Therapeutics

San Francisco Bay Area: Crowne Plaza Foster City; available as webcast to other PBSS chapters

Major Sponsor



PBSS Gold Sponsor

**WILSON
SONSINI**

Exhibiting vendors



New Vendor Recruitment incentive: if a new vendor joins a PBSS event thanks to your referral, we'll give you a free show or a free workshop attendance registration!

Registration: <https://www.pbss.org>

- Regular Attendees: \$295 (Registration closes one day before the event or when full)
- Academic or Out-of-Pocket: \$45 (Registration closes five days before the event)

